Fresenius Medical Care stock closes at EUR 44.51 after Q2 growth
Published on 10/07/2026 at 14:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius Medical Care (ISIN DE0005785802) closed at EUR 44.51 on Xetra on October 7, 2026, as the dialysis provider's latest operating figures continued to shape the stock's valuation. According to the Fresenius Medical Care investor page, operating income rose 23 percent in the second quarter of 2026 and the company confirmed its full-year outlook.
Q2 growth remains the key driver
Revenue reached EUR 4.861 billion in Q2 2026, compared with EUR 4.792 billion in Q2 2025. The increase was accompanied by higher profitability, with the company highlighting stronger performance in its Care Delivery segment.
The operating improvement matters because FMC is executing its FME Reignite strategy while facing reimbursement, treatment-volume and regulatory pressures. The company said underlying operating income improved 34 percent after adjusting for positive TDAPA effects, with reimbursement rates and revenue-cycle management supporting the result.
China restructuring adds a cost burden
Fresenius Medical Care is also reshaping its China strategy. The company plans to discontinue production and distribution of the 4008A hemodialysis system and exit its peritoneal dialysis business in the country.
According to Boerse Express on October 1, 2026, Berenberg cut its price target from EUR 60 to EUR 42 and lowered its rating to Hold. The report also cited EUR 110 million in expected one-time costs linked to the China restructuring.
Consensus stays close to the market
The valuation picture is more measured in US trading. A consensus published by Bullstory on October 6, 2026, showed a Hold rating from 7 analysts and an average target of USD 23.51, versus a reference price of USD 22.65. The same consensus listed targets from USD 16.87 to USD 37.12, showing a wide range of views.
Results date is November 3
For investors, the next firm checkpoint is the Q3 2026 report. Fresenius Medical Care's investor calendar lists November 3, 2026, for the earnings release and conference call, with the quarterly report scheduled for November 6, 2026.
Stock closes at EUR 44.51
Fresenius Medical Care stock closed at EUR 44.51 on Xetra on October 7, 2026. The combination of 23 percent Q2 operating-income growth and EUR 110 million of planned China restructuring costs leaves execution and cost control as the central valuation themes.
Fresenius Medical Care stock facts
- Company: Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- WKN: 578580
- Ticker: FME
- Trading venue: Xetra
- Price (as of October 7, 2026): EUR 44.51, closing price
- Sector / Industry: Healthcare / Medical Care Facilities
- Index membership: MDAX
Upcoming dates for Fresenius Medical Care stock
- October 12, 2026: Value-Based Care Expert Call
- November 3, 2026: Q3 2026 earnings release and conference call
- November 6, 2026: Q3 2026 financial report
